Syngene
Syngene International Limited, commonly referred to as Syngene, is a leading global contract research and manufacturing organisation headquartered in Bengaluru, India. Founded in 1993, Syngene has established itself as a key player in the biopharmaceutical industry, providing integrated research and development services to clients across the globe. With a strong presence in North America, Europe, and Asia, Syngene offers a diverse range of services, including drug discovery, development, and manufacturing. The company is renowned for its innovative approach, leveraging cutting-edge technologies to deliver high-quality solutions tailored to client needs. Syngene's commitment to excellence has earned it a prominent market position, with notable achievements in collaborations with major pharmaceutical companies. Its unique blend of scientific expertise and operational efficiency sets Syngene apart in the competitive landscape of life sciences.
DitchCarbon Score
How does Syngene's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Syngene's score of 57 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Syngene's reported carbon emissions
In 2023, Syngene International Limited reported total greenhouse gas emissions of approximately 89,418,000 kg CO2e, comprising 6,101,000 kg CO2e from Scope 1, 18,765,000 kg CO2e from Scope 2, and 89,418,000 kg CO2e from Scope 3 emissions. This reflects a commitment to reducing absolute Scope 1 and 2 emissions by 54.6% by FY2033, using FY2023 as the base year. Additionally, Syngene aims for 81.6% of its suppliers, covering emissions from purchased goods and services, capital goods, and upstream transportation and distribution, to have science-based targets by FY2028. In previous years, emissions were also significant, with 2022 figures showing 90,297,000 kg CO2e in Scope 3 emissions alone. The company has set ambitious targets aligned with the Science Based Targets initiative (SBTi), focusing on substantial reductions in its operational carbon footprint. Syngene's long-term goal includes achieving net-zero emissions across all scopes by 2050, demonstrating its commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 3,440,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 11,263,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 62,847,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Syngene is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
